Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis by Ortegon, M.M. (Monica) et al.
Cost-Effectiveness of Prevention and
Treatment of the Diabetic Foot
A Markov analysis
MONICA MARIA ORTEGON, MD1,2
WILLIAM KEN REDEKOP, PHD2
LOUIS WILHELMUS NIESSEN, PHD2
OBJECTIVE — To estimate the lifetime health and economic effects of optimal prevention
and treatment of the diabetic foot according to international standards and to determine the
cost-effectiveness of these interventions in the Netherlands.
RESEARCH DESIGN AND METHODS — A risk-based Markov model was developed
to simulate the onset and progression of diabetic foot disease in patients with newly diagnosed
type 2 diabetes managed with care according to guidelines for their lifetime. Mean survival time,
quality of life, foot complications, and costs were the outcome measures assessed. Current care
was the reference comparison. Data from Dutch studies on the epidemiology of diabetic foot
disease, health care use, and costs, complemented with information from international studies,
were used to feed the model.
RESULTS — Compared with current care, guideline-based care resulted in improved life
expectancy, gain of quality-adjusted life-years (QALYs), and reduced incidence of foot compli-
cations. The lifetime costs of management of the diabetic foot following guideline-based care
resulted in a cost per QALY gained of$25,000, even for levels of preventive foot care as low as
10%. The cost-effectiveness varied sharply, depending on the level of foot ulcer reduction
attained.
CONCLUSIONS — Management of the diabetic foot according to guideline-based care im-
proves survival, reduces diabetic foot complications, and is cost-effective and even cost saving
compared with standard care.
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D iabetes is becoming one of the mostcommon chronic diseases in theNetherlands. An age-related in-
crease in the prevalence of diabetes of 32–
36% is estimated for the period from
1995 to 2010, at the end of which
400,000–500,000 cases are expected (1).
Diabetes is a leading cause of morbidity
and mortality, imposing a burden on bud-
get and human resources (2,3). Diabetic
patients account for 12 and 18% of the
total mortality of Dutch men and women,
respectively (4), and 2.5% of total Dutch
health care costs (5).
A costly complication affecting pa-
tients with diabetes is the diabetic foot.
The high therapeutic costs and low qual-
ity of life caused by lower extremity am-
putation (LEA), the most severe conse-
quence of the disease, account for a large
part of these expenses. It is estimated that
80% of LEAs are preceded by foot ulcers.
Accordingly, it has been demonstrated
that preventing the development of foot
ulcers in patients with diabetes reduces
the frequency of LEAs by 49–85% (6).
Given the above, national clinical
guidelines on the prevention and treat-
ment of the diabetic foot have been re-
cently issued as part of a project initiated
by the Dutch Ministry of Health in 1998.
The strategies contained in the guidelines
follow the principles outlined in the In-
ternational Consensus of the Diabetic
Foot (7). Cornerstones of guidelines-
based care are intensive glycemic control
(IGC) and optimal foot care (OFC). Al-
though health benefits and economic ef-
ficiency of intensive blood glucose
control (8) and foot care programs (9–14)
have been individually reported, the
health and economic outcomes and the
cost-effectiveness of both interventions
have not been determined. Moreover, the
long-term costs and outcome estimates of
these interventions remain unknown;
most of the few cost-effectiveness studies
performed in diabetic foot management
are based on short-term models, the re-
sults of which do not allow adequate es-
timates of the quality-adjusted life-years
(QALYs) saved by these interventions.
To address these issues, we estimated
the lifetime health and economic effects of
the prevention and treatment of the dia-
betic foot according to international stan-
dards and de te rmined i t s cos t -
effectiveness relative to current care in a
group of diabetic patients in the
Netherlands.
RESEARCH DESIGN AND
METHODS — A Markov model was
built to simulate the health and economic
outcomes of optimal care of the diabetic
foot in a hypothetical population of dia-
betic patients. Markov models are well-
recognized methods for analyzing clinical
and economic consequences of medical
decisions, particularly in long-term dis-
eases characterized by repeating risks of
events over time. Because of its chronic
nature and the recurrent character of its
major adverse outcomes, foot ulcers and
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amputations, diabetic foot disease fulfills
these criteria.
In this study, diabetic foot pathology
was modeled by 13 health states describ-
ing the spectrum of the disease from
causes to consequences: three risk health
states, six wound type states, and four
outcome states were included. Cohorts of
10,000 patients with newly diagnosed
type 2 diabetes were followed through the
model individually over their lifetime. In
the simulations, optimal treatment and
prevention were compared with present
level of care. The clinical outcomes mea-
sured were life expectancy, QALYs, and
incidence of foot ulcers and amputations.
The economic outcomes studied were
mean expected total lifetime cost and in-
cremental cost-effectiveness ratio (ICER).
Model structure
Health states and transition probabili-
ties. Health states were defined consider-
ing their clinical relevance within the
history of the disease and their association
with different health outcomes and re-
source costs (Fig. 1). The first three health
states represented pathophysiologic pre-
cursors for development of ulcers. The
presence or absence of these factors con-
fer different risks for ulceration and, thus,
have been included in the model as dia-
betic foot risk (DFR) states. Based on the
classification system of the International
Working Group on the Diabetic Foot
(IWGDF) (7), these states were defined
as: DFR1, no neuropathy; DFR2, sensory
neuropathy; and DFR3, sensory neurop-
athy and deformity or peripheral vascular
disease. Previous ulcer or amputation, the
fourth risk factor identified by the
IWGDF, was represented in the model by
the healed and postminor amputation
states since the entrance to these states
implied the occurrence of a previous epi-
sode of an ulcer or amputation.
The six wound health states reflect
important characteristics of diabetic foot
lesions, namely depth, presence of isch-
emia, and infection, and they attempt to
reconcile two established wound classifi-
cation systems: Wagner’s (15) and the
University of Texas (16) classification sys-
tems. The remaining four health states en-
compass all possible outcomes of the
diabetic foot disease: healed, amputation
(minor or major), and death.
Patients progressed to other health
states, remained in the same state, or died,
depending on the associated probabilities
for each transition. Six-month transition
probabilities were assigned for movement
between the health states. Mean age at en-
try was 61 years, corresponding to the
mean age of diagnosis of type 2 diabetes in
the Netherlands (17). All patients began
the model in DFR1 (88.5%) or DFR2
(11.5%) states, concurring with the prev-
alence of sensory neuropathy at time of
diagnosis of diabetes (18).
Information on probabilities of mor-
bid and mortal events was derived from
studies on incidence and prevalence of di-
abetic foot pathology published from
1996 to 2002. Priority was given to na-
Figure 1—Health states and transition paths. Not shown is the chance of death for all health states. The permanency in the ischemic state refers to
treated ischemia. DFR1, no neuropathy; DFR2, sensory neuropathy; DFR3, sensory neuropathy and deformity or peripheral vascular disease.
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tional published articles and prospective
cohort studies to obtain the best reflection
of the history of the disease in a Dutch
setting. To ensure consistency, all inter-
national studies used pertained to the
same research group: the University of
Texas study group. Data derived from the
U.K. Prospective Diabetes Study group
were only used in the transition to sensory
neuropathy. These studies were selected
based on comparability with Dutch dia-
betic population characteristics, sample
size, follow-up period, reporting on vari-
ables of interest, and overall quality. Tran-
sition probabilities and study sources are
summarized in Table 1.
Morbidity. Core information was ob-
tained from the only Dutch prospective
cohort study on diabetic foot disease (17).
An annual ulcer incidence rate of 2.1%
and an amputation incidence rate of 0.6%
were among the reference country–
specific parameters derived from this
study and adopted in the model.
Transition probabilities to the differ-
ent ulcer states were specific for each of
the four risk categories. Incidence rates
per risk subgroup were calculated using
information from two of the few prospec-
tive cohort studies reporting ulcer inci-
dence following the risk classification
system of the IWGDF (19,20). Ulcer dis-
tribution per risk group was derived from
local and international studies (21–23). A
recategorization of the wound types was
performed to meet the health states defi-
nition of the model. The progressions and
associated probabilities of the wound
types were derived from longitudinal
studies on clinical outcomes of foot ulcers
(22,23). In general, once in a wound state,
four possible transitions were allowed:
the wound healed primarily, the wound
healed after amputation, the lesion re-
mained unhealed, or the patient died.
Wound healing probabilities were calcu-
lated as the residual of the probability of
the other transition(s). The healed and
postminor amputation states were con-
sidered to have the same wound progres-
s ions and as soc i a t ed t r ans i t i on
probabilities. In the postmajor amputa-
tion state, the transition to a new ulcer
was not allowed; in this state, patients ei-
ther remained in the same state or died.
Mortality. Data were obtained from
studies reporting on mortality of diabetic
patients in the Netherlands (24,25). Mor-
tality rates of the risk states were age spe-
cific. Age ranges per risk categories were
T
able
1—
Six-m
onth
transition
probabilities
and
input
values
for
standard
care
From
T
o
2
3
T
ransition
probabilities
U
tili-
ties
C
osts
D
FR
1
D
FR
2
D
FR
3
Preulcer
Super-
ficial
ulcer
Superfi-
cial
infection
D
eep
ulcer
A
bscess/
osteom
y-
elitis
Ischem
ia
H
ealed
Post
m
inor
am
pu-
tation
Post
m
ajor
am
pu-
tation
D
eath
R
eferences
D
FR
1
95.7
1.99
—
0.2
0.02
0.006
—
—
—
—
—
—
2
17–22,24
0.84
108
D
FR
2
—
90
5
0.6
0.06
0.01
0.01
0.04
—
—
—
—
4.5
17,19–22,24
0.74
108
D
FR
3
—
94.8
0.03
0.18
0.11
0.11
0.20
0.07
—
—
—
4.5
17,19,20,22–24
0.74
108
Preulcer
—
—
—
—
98*
—
—
—
—
—
—
—
2*
23,24
0.75
108
95.5†
4.5†
90‡
10‡
Superficialulcer
—
—
—
—
—
—
—
—
—
98*
—
—
2*
23,24
0.75
874
95.5†
4.5†
90‡
10‡
Superficialinfection
—
—
—
—
—
—
—
8
—
87.5*†
—
—
4.5*†
22–24
0.70
1,181
82‡
10‡
D
eep
ulcer
—
—
—
—
—
—
—
—
—
95.5†
—
—
4.5†
22–24
0.75
1,872
90‡
10‡
A
bscess/osteom
yelitis
—
—
—
—
—
—
—
16.5
—
21.5
20.5
31.5
10
22–24
0.59
4,834
Ischem
ia
—
—
—
—
—
—
—
—
22.3
22.7
17.4
27.2
10
22–24
0.59
2,621
H
ealed
—
—
—
0.21
1.3
0.77
0.78
1.43
0.54
84.9
—
—
10
17,19,20,23,24
0.68
108
Postm
inor
am
putation
—
—
—
0.21
1.3
0.77
0.78
1.43
0.54
—
76
17
1.69
17,19,20,23,25
0.68
923
Postm
ajor
am
putation
—
—
—
—
—
—
—
—
—
—
—
89
11
25
0.62
1,325
D
ata
for
transition
probabilities
are
percentages.*R
isk
1;†R
isk
2–3;‡R
isk
4.T
ransition
from
D
FR
1
to
D
FR
2
corresponds
to
baseline
incidence
rates.D
iscrepancies
due
to
rounding.C
osts
expressed
as
1999
U
.S.dollars.
Ortegon, Redekop, and Niessen
DIABETES CARE, VOLUME 27, NUMBER 4, APRIL 2004 903
calculated based on mean duration of di-
abetes reported in a previous study (19).
Risk group 1 patients were assigned the
mortality rate of the diabetic population
in the Netherlands aged 55– 64 years
(newly diagnosed diabetic patients). Risk
groups 2 and 3 were assigned the mortal-
ity of diabetic patients aged 65–74 years,
and risk group 4 patients were assigned
the mortality of diabetic patients aged
75 years (24). Similarly, these mortality
rates were assigned to the wound states
according to severity and risk category.
Interventions
The treatment effects of conventional gly-
cemic control and IGC simulated in the
model were based on U.K. Prospective Di-
abetes Study results (18). The neuropathy
rates reported for both groups were incor-
porated into our model in the transition
from DFR1 (no neuropathy) to DFR2
(sensory neuropathy).
OFC according to guidelines includes
professional protective foot care, educa-
tion of patients and staff, regular inspec-
tion of the feet, identification of the high-
risk patient, treatment of nonulcerative
lesions, and a multidisciplinary approach
to established foot ulcers. These strategies
have been reported to decrease the inci-
dence of LEA by 49–85% (6). Because the
major goal of these interventions is to de-
crease the occurrence of foot pathology,
the effect of OFC in the model was incor-
porated by reducing the probabilities of
development of foot lesions. To overcome
the uncertainty around the decrease in
frequency of foot lesions required to at-
tain a decrease in LEA, the probabilities
describing the transitions to the different
wound states were varied across a range of
10–90% and the effects on LEA rates were
recorded.
The clinical and economic outcomes
of the two intervention strategies con-
tained in the guidelines (IGC and OFC)
were analyzed separately and in combina-
tion to determine their individual weight
and additive impact on the results.
Costs
Resource use associated with the various
health states and transitions was obtained
from a published study comparing stan-
dard and intensive treatment protocols in
general practices in the Netherlands
(26,27) and from an economic study on
the treatment of diabetic foot ulcers (28).
Only direct medical costs were consid-
ered. The costs of each health state were
determined by the health care utilization
associated with that state and included
expenses such as labor, medication, labo-
ratory, materials (shoes, insoles, contact
casts), and procedure (diagnostic tests,
debridement, bone resection) (Table 1
and Fig. 3). Costs used in the model were
expressed as 1999 U.S. dollars and dis-
counted by 3%.
Utilities
The utility weights needed to calculate
QALY were derived from a Dutch study
on foot ulcers and amputation state valu-
ations (29). Utility weights ranged from 0
to 1, where 0 represented a quality of life
equal to death and 1 represented perfect
health (Table 1).
Utilities were discounted by 3%.
Sensitivity analysis
Sensitivity analyses were performed on ef-
fectiveness of preventive foot care strate-
gies (level of foot lesion reduction), utility
weights, and costs. The utility weights
were varied according to the results from
a previous study on quality of life and foot
ulcers (30). These values were adapted to
meet our ulcer categorization. Costs were
changed by varying the length of stay of
inpatient care. The length of stay reported
for inpatient care of foot ulcers in the U.S.
was used as a reference in the sensitivity
analysis (31). This model was constructed
using TreeAge (DATA 3.5) software.
RESULTS — The lifetime health and
economic outcomes for patients under
standard care and guidelines care are
summarized in Table 2. Results are shown
for the three types of guidelines care sce-
narios considered: IGC, OFC, and IGC
OFC. For the cohorts under OFC inter-
vention, results are shown for the lowest
(10%) and highest (90%) level of ulcer
reduction simulated.
Table 2—Clinical and economic outcomes of standard care and guidelines care simulations
Life expectancy
Standard
care
Guideline care
IGC
10% foot lesion reduction 90% foot lesion reduction
OFC IGC  OFC OFC IGC  OFC
Life expectancy (years) 8.14 8.21 8.15 8.23 8.33 8.41
SD of life expectancy (years) 0.43 0.43 0.43 0.43 0.44 0.44
Difference in life expectancy NA 0.07 0.01 0.09 0.19 0.27
QALY 6.49 6.56 6.50 6.58 6.65 6.74
SD of QALY 0.34 0.35 0.34 0.35 0.35 0.35
Difference in QALY NA 0.07 0.01 0.09 0.16 0.25
Total lifetime costs 2,142 4,386 4,343 4,352 4,088 4,107
SD of total lifetime costs 259 337 329 323 232 232
Difference in total lifetime costs NA 2,244 2,201 2,210 1,946 1,965
ICER NA 32,057 220,100 24,556 12,163 7,860
Cumulative incidence of ulcers (%) 17.8 17.7 15.8 15.84 1.31 1.28
Cumulative incidence of amputations (%) 3.62 3.46 3.28 3.24 0.25 0.24
Ulcer reduction (%) NA 0.56 11.2 11.2 92.7 92.8
Amputation reduction (%) NA 4.4 9.4 10.5 93.1 93.4
Costs expressed as 1999 U.S. dollars. SD of mean was derived using 10,000 Monte Carlo simulations, each consisting of 100 individuals.
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Model validity
The health outcomes results of the cohort
following standard care were comparable
to figures reported for diabetic patients in
the Netherlands. The undiscounted mean
life expectancy was 14 years (discounted
mean life expectancy, 8.1 years). In the
10,000 patients followed until death, a
total of 1,780 ulcer episodes occurred,
corresponding to a cumulative ulcer inci-
dence of 17.8% and an annual ulcer inci-
dence of 2.2% (mean annual ulcer
incidence for the Netherlands is 2.1%)
(17). The number of amputations ob-
served was 362 (250 major and 112 mi-
nor), corresponding to a cumulative
incidence of 3.6% and an annual inci-
dence of 0.4% (mean annual amputation
incidence reported for the Netherlands is
0.6%) (17). Mean lifetime costs totaled
$2,142.
Health and economic outcomes
All cohorts of patients simulated for the
different scenarios of guidelines care re-
sulted in improved life expectancy,
QALYs gained, and reduced incidence of
foot ulcers and LEA compared with stan-
dard care. The largest effects on these out-
comes were obtained when patients
received IGC  OFC. When comparing
the independent health effects of the two
guidelines strategies, OFC resulted in a
greater reduction in ulcer and amputation
rates than IGC. Moreover, patients who
received IGC  OFC showed approxi-
mately the same LEA incidence as patients
who received OFC alone. The LEA de-
crease obtained was proportional to the
level of foot ulcer reduction attained.
The mean total lifetime costs of a pa-
tient under either of the three guidelines
care scenarios ranged from $4,088 to
$4,386. For patients receiving IGC 
OFC, these costs resulted in $25,000
per QALY gained (relative to standard
care). For patients receiving IGC alone,
the ICER obtained was $32,057 per
QALY gained, and for those receiving
OFC alone, this ICER ranged from
$12,169 to $220,100 per QALY gained,
depending on the level of ulcer reduction
attained.
Figure 2 is a graphical representation
of the additional costs, QALYs gained,
and ICER of the three guidelines care sce-
narios compared with standard care. All
levels of foot ulcer reduction (10–90%)
considered in the sensitivity analysis are
represented. Also shown are the results of
the sensitivity analyses performed on the
QALY weights and length-of-stay input
parameters. The results of the simulations
for the combined scenario (IGC  OFC)
were used to illustrate the effects of these
variations (curves to the right). Results are
shown for both input parameters varied
simultaneously and separately (Fig. 3).
ICERs of$25,000 were obtained for
levels of preventive foot care of10% for
patients under IGC OFC and for levels
of preventive foot care of 40% for pa-
tients receiving OFC alone (Table 2).
Sensitivity analyses
Increasing the effectiveness of preventive
foot care in patients under OFC and IGC
 OFC resulted in more QALYs gained,
lower costs, and a more favorable ICER.
The results of the simulations for the com-
bined scenario (IGC OFC) were rather
insensitive to changes in utility weights
and costing parameters. Similar results
were obtained for parameter variations in
the other two scenarios (IGC and OFC
separately).
CONCLUSIONS — The results of
this study suggest that IGC  OFC re-
duces foot ulcers and amputations and
leads to an improvement in life expect-
ancy. Greater health benefits are obtained
with higher levels of foot ulcer preven-
tion. Although care according to guide-
lines increases health costs, the cost per
QALY gained is$25,000, even for levels
of preventive foot care as low as 10%.
ICERs of this order are cost-effective ac-
cording to the stratification of interven-
tions for diabetes recently proposed (32).
OFC strategy alone is only cost-
effective at levels of preventive foot care
40%. In a previous economic study per-
formed in Sweden (13), intensified foot
care intervention was cost-effective when
Figure 2—Costs, effects, and sensitivity analysis results for guidelines care scenarios compared with standard care. Curves correspond to foot ulcer
reduction levels of 10–90% (10% intervals). Black symbols represent simulation results obtained using reference input parameters; white symbols
represent simulation results obtained using alternative input parameters results.F, IGC point estimate;Œ, OFC curve;f, IGCOFC curve;‚, IGC
 OFC curve using alternative utility weights;E, IGC OFC curve using alternative costs;, IGC OFC curve using alternative utility weights
and costs simultaneously.
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a 25% reduction in incidence of foot ul-
cers and amputations was assumed. This
difference in the level of preventive foot
care between their study and our study,
albeit not large, may be attributed to dif-
ferences in model architecture, follow-up
period, and information used in the mod-
els, including country-specific parameters
such as incidence of foot complications,
prevalence of foot wounds, and costs.
The cost-effectiveness of IGC alone
was estimated to be $32,057 per QALY
and the reduction in incidence of LEA was
estimated to be 4.4%. Our results are
comparable to those reported by the Cen-
ters for Disease Control and Prevention
(CDC) group (8), in which an ICER of
$41,384 and an LEA reduction of 3%
were reported. IGC falls into the category
of a possibly cost-effective intervention in
the management of the diabetic foot. Al-
though it does not produce significant re-
duction in foot ulcers and LEA, its
effectiveness resides in the slowing of
neuropathy progression rates.
Extrapolating our results to a practi-
cal situation, if IGC  OFC was to be
given to all diabetic patients in the Neth-
erlands, with the aim of reducing LEA by
50% (St. Vincent’s declaration), the cost
per QALY gained would be $12,165 and
the cost for managing diabetic ulcers and
amputations would decrease by 53 and
58%, respectively. From a policy perspec-
tive, this is clearly cost-effective and cost
saving compared with current care. From
a clinical perspective, this goal is achiev-
able considering that LEA reductions of
49–85% have been reported in the liter-
ature for strategies containing only foot
care preventive measures (6). For OFC
alone, these results would be achieved at
an ICER of $22,812, which is twice the
ratio seen for the combined scenario.
The results of our study are supported
by the robustness of the model. The
agreement of the epidemiologic outputs
with known data on incidence and prev-
alence of the diabetic foot provides evi-
dence of the model’s ability to adequately
reflect disease progression. In building
the model, great effort was put into col-
lecting updated, representative, and con-
sistent information; therefore, the
conclusions that can be drawn from it are
valid and the probability for bias is small.
Although the input parameters used were
based on a Dutch setting, the model’s
structure has worldwide applicability.
In conclusion, guidelines care com-
prising metabolic and foot care interven-
tions combined is cost-effective and may
even be cost saving in the management of
the diabetic foot in the Netherlands. A
valid and comprehensive Markov model
that can be used for future cost-
effectiveness analysis of diabetic foot dis-
ease prevention has been developed.
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